One example is that omalizumab which is a clinically tested and approved humanized IgG1 that binds to circulating IgE, and unlike any other anti-IgEs, it does not bind to IgE that is already bound to FcεRI on the surface of cells [50], thereby decreases the cell-bound IgE and tissue infiltration of eosinophils and mediator release, resulting in the relief of allergic inflammation and asthma symptoms. Here, FCER1A is linked to asthma.